In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system.

In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system.
复制标题

DOI:
10.1038/nature13902
复制
发表时间:
2014-12-18
期刊:
影响因子:
64.8
通讯作者:
Ventura, Andrea
Ventura, Andrea
中科院分区:
综合性期刊1区
文献类型:
--
作者:
Maddalo, Danilo;Manchado, Eusebio;Concepcion, Carla P.;Bonetti, Ciro;Vidigal, Joana A.;Han, Yoon-Chi;Ogrodowski, Paul;Crippa, Alessandra;Rekhtman, Natasha;de Stanchina, Elisa;Lowe, Scott W.;Ventura, Andrea

文献摘要

参考文献

被引文献

相似文献

染色体重排在人类癌症的发病机制中起核心作用,并且通常导致可治疗的基因融合体的表达。最近发现的一个例子是棘皮动物微管相关蛋白样4(EML 4)和间变性淋巴瘤激酶(ALK)基因之间的融合,由2号染色体短臂上的倒位产生:inv(2)(p21 p23)。EML 4-ALK癌基因在人非小细胞肺癌(NSCLC)亚组中检出,具有临床相关性,因为它赋予了对ALK抑制剂的敏感性。尽管它们很重要,但在小鼠中模拟这些遗传事件已被证明具有挑战性,需要对种系进行复杂的操作。在这里,我们描述了一种使用病毒介导的CRISPR/Cas9系统递送至成年动物的体细胞来体内诱导特异性染色体重排的有效方法。我们将其应用于产生Eml 4-Alk驱动的肺癌的小鼠模型。所得肿瘤总是具有Em 14-Alk转化,表达Em 14-Alk融合基因,显示ALK+人NSCLC的典型组织病理学和分子特征,并对ALK抑制剂治疗有反应。这里描述的一般策略大大扩展了我们在小鼠和其他生物体中建立人类癌症模型的能力。
Chromosomal rearrangements play a central role in the pathogenesis of human cancers and often result in the expression of therapeutically actionable gene fusions. A recently discovered example is a fusion between the Echinoderm Microtubule-associated Protein-like 4 (EML4) and the Anaplastic Lymphoma Kinase (ALK) genes, generated by an inversion on the short arm of chromosome 2: inv(2)(p21p23). The EML4-ALK oncogene is detected in a subset of human non-small cell lung cancers (NSCLC) and is clinically relevant because it confers sensitivity to ALK inhibitors. Despite their importance, modeling such genetic events in mice has proven challenging and requires complex manipulation of the germline. Here we describe an efficient method to induce specific chromosomal rearrangements in vivo using viral-mediated delivery of the CRISPR/Cas9 system to somatic cells of adult animals. We apply it to generate a mouse model of Eml4-Alk-driven lung cancer. The resulting tumors invariably harbor the Eml4-Alkinversion, express the Eml4-Alk fusion gene, display histo-pathologic and molecular features typical of ALK+ human NSCLCs, and respond to treatment with ALK-inhibitors. The general strategy described here substantially expands our ability to model human cancers in mice and potentially in other organisms.
DOI: 10.1101/gr.147314.112
发表时间: 2013-07
期刊: Genome research
影响因子: 7
作者:
Piganeau M;Ghezraoui H;De Cian A;Guittat L;Tomishima M;Perrouault L;René O;Katibah GE;Zhang L;Holmes MC;Doyon Y;Concordet JP;Giovannangeli C;Jasin M;Brunet E
通讯作者: Brunet E
DOI: 10.1126/science.1225829
发表时间: 2012-08-17
期刊: SCIENCE
影响因子: 56.9
作者:
Jinek, Martin;Chylinski, Krzysztof;Charpentier, Emmanuelle
通讯作者: Charpentier, Emmanuelle
DOI: 10.1038/nrc2442
发表时间: 2008-08
期刊: Nature reviews. Cancer
影响因子: --
作者:
通讯作者: --
DOI: 10.1093/embo-reports/kvd021
发表时间: 2000-08-01
期刊: EMBO REPORTS
影响因子: 7.7
作者:
Collins, EC;Pannell, R;Rabbitts, TH
通讯作者: Rabbitts, TH
DOI: 10.1073/pnas.0902076106
发表时间: 2009-06-30
影响因子: 11.1
作者:
Brunet, Erika;Simsek, Deniz;Jasin, Maria
通讯作者: Jasin, Maria